{"id":"irsogladine","rwe":[{"pmid":"40520453","year":"2025","title":"Hyaluronic acid and chondroitin sulfate-based medical devices: formulations, esophageal mucosal protection, and their place in the management of GERD.","finding":"","journal":"Therapeutic advances in gastroenterology","studyType":"Clinical Study"},{"pmid":"39695346","year":"2025","title":"Sustainable Synthesis of Substituted 1,3,5-Triazines by [ONO]-Pincer-Supported Nickel(II) Complexes via an Acceptorless Dehydrogenative Coupling Strategy.","finding":"","journal":"The Journal of organic chemistry","studyType":"Clinical Study"},{"pmid":"36676718","year":"2022","title":"Protective Effect of Irsogladine against Aspirin-Induced Mucosal Injury in Human Induced Pluripotent Stem Cell-Derived Small Intestine.","finding":"","journal":"Medicina (Kaunas, Lithuania)","studyType":"Clinical Study"},{"pmid":"33619857","year":"2021","title":"Using Theory To Extend the Scope of Azobenzene Drugs in Chemotherapy: Novel Combinations for a Specific Delivery.","finding":"","journal":"ChemMedChem","studyType":"Clinical Study"},{"pmid":"32926748","year":"2021","title":"Irsogladine maleate alters expression of a tight junction protein in portal hypertensive gastropathy.","finding":"","journal":"Journal of gastroenterology and hepatology","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Anti-Ulcer Agents","category":"pharmacology"},{"label":"Anticarcinogenic Agents","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Gastrointestinal Agents","category":"pharmacology"},{"label":"Protective Agents","category":"pharmacology"},{"label":"Radiation-Protective Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"dicloguamine","offLabel":[],"synonyms":["irsogladine","dicloguamine","irsogladine maleate"],"timeline":[],"approvals":[],"brandName":"Dicloguamine","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Imagine your body's cells have locks on them, and Dicloguanine has a key that fits into one of those locks. When it binds, it changes the way the lock works, allowing the cell to function differently. This can help treat various conditions by changing the way cells behave.","oneSentence":"Dicloguanine works by binding to a specific target, altering its function to produce a therapeutic effect.","technicalDetail":"Dicloguanine's mechanism of action is not well-documented, but it is likely to involve binding to a specific protein or receptor, altering its activity and leading to downstream effects on cellular function."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1484","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=IRSOGLADINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IRSOGLADINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:09:44.773234","biosimilars":[],"competitors":[],"genericName":"irsogladine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05249725","phase":"PHASE4","title":"Therapeutic Effect of Isogladine Maleate on Small Intestinal Mucosal Injury Associated With NSAIDS in Population","status":"UNKNOWN","sponsor":"Lee's Pharmaceutical Limited","startDate":"2022-04","conditions":["NSAIDs-associated Intestinal Mucosal Injury"],"enrollment":100,"completionDate":"2023-04"},{"nctId":"NCT03509831","phase":"PHASE1","title":"[KJ-INT-002] BE Study","status":"UNKNOWN","sponsor":"Kukje Pharma","startDate":"2017-11-02","conditions":["Gastritis"],"enrollment":37,"completionDate":"2018-04"},{"nctId":"NCT02759224","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics of Lafutidine and Irsogladine Maleate Tablet","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2016-04-15","conditions":["Gastric Ulcer"],"enrollment":34,"completionDate":"2016-12-29"},{"nctId":"NCT02581696","phase":"PHASE1","title":"The Drug-drug Interaction and Safety of Lafutidine and Irsogladine Maleate in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2015-08","conditions":["Peptic Ulcer"],"enrollment":24,"completionDate":"2015-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"QBX79NZC1D","CHEBI":"CHEBI:93307","INN_ID":"6223","UMLSCUI":"C0063879","ChEMBL_ID":"CHEMBL136497","KEGG_DRUG":"D01658","DRUGBANK_ID":"DB13056","PUBCHEM_CID":"3752","SECONDARY_CAS_RN":"84504-69-8","MESH_SUPPLEMENTAL_RECORD_UI":"C041836"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":83,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2025","pmid":"40520453","title":"Hyaluronic acid and chondroitin sulfate-based medical devices: formulations, esophageal mucosal protection, and their place in the management of GERD.","journal":"Therapeutic advances in gastroenterology"},{"date":"2025 Jan 10","pmid":"39695346","title":"Sustainable Synthesis of Substituted 1,3,5-Triazines by [ONO]-Pincer-Supported Nickel(II) Complexes via an Acceptorless Dehydrogenative Coupling Strategy.","journal":"The Journal of organic chemistry"},{"date":"2022 Dec 31","pmid":"36676718","title":"Protective Effect of Irsogladine against Aspirin-Induced Mucosal Injury in Human Induced Pluripotent Stem Cell-Derived Small Intestine.","journal":"Medicina (Kaunas, Lithuania)"},{"date":"2021 Jun 7","pmid":"33619857","title":"Using Theory To Extend the Scope of Azobenzene Drugs in Chemotherapy: Novel Combinations for a Specific Delivery.","journal":"ChemMedChem"},{"date":"2021 May","pmid":"32926748","title":"Irsogladine maleate alters expression of a tight junction protein in portal hypertensive gastropathy.","journal":"Journal of gastroenterology and hepatology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dicloguanine, also known as IRSOGladine, is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it is not known if it is FDA approved or off-patent. The approved indications for Dicloguanine are also unknown. As a small molecule, it is likely to be administered orally, but its pharmacokinetic properties, such as half-life and bioavailability, are not well-documented. Further research is needed to understand the safety and efficacy of Dicloguanine.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}